LY2109761, also known as LY-2109761, is a small molecule inhibitor of the TGF-β signaling pathway. It has been developed as a potential treatment for various types of cancer, including pancreatic cancer, glioblastoma, and lung cancer.
Chemical name: 4-[4-(6-methoxyquinolin-4-yl)-5-methylthiazol-2-ylamino]benzoic acid Molecular formula: C23H19N3O3S Formula weight: 421.48 g/mol CAS No: 700874-71-1
Top Ten Keywords from Google:
Synonyms: LY-2109761, LY2109761, 700874-71-1
Health benefits of this product:
LY2109761 has the potential to benefit patients with various types of cancer, particularly those with tumors that are resistant to chemotherapy or other standard treatments. By inhibiting the TGF-β signaling pathway, it can help slow or stop the growth of cancer cells, potentially leading to improved outcomes for patients.
Potential effects:
The potential effects of LY2109761 include reducing the size and spread of tumors, improving overall survival rates, and potentially overcoming chemotherapy resistance in some patients. In preclinical studies, LY2109761 has also been shown to modulate the tumor microenvironment and enhance the anti-tumor immune response.
Product mechanism:
LY2109761 works by inhibiting the TGF-β signaling pathway, which plays a critical role in regulating cell growth, differentiation, and apoptosis. When TGF-β binds to its receptor on the cell surface, it activates downstream signaling pathways, including the Smad proteins, which can promote cell proliferation and suppress the immune response. LY2109761 blocks these pathways by binding to the ATP-binding site of the TGF-β receptor, preventing its activation and downstream signaling.
Safety:
Like all medications, LY2109761 can have side effects, and it should only be taken under the supervision of a healthcare professional. Some potential side effects of LY2109761 include fatigue, nausea, diarrhea, decreased appetite, and elevated liver enzymes. In clinical trials, some patients experienced more serious side effects, such as hypertension and cardiac events. As such, it is important for patients taking LY2109761 to have regular check-ups with their healthcare providers to monitor their overall health.
Side effects:
Common side effects of LY2109761 include fatigue, nausea, diarrhea, decreased appetite, and elevated liver enzymes. Some patients may also experience more serious side effects, such as hypertension and cardiac events. It is important for patients taking LY2109761 to report any side effects to their healthcare provider right away.
Dosing information:
The dosing of LY2109761 depends on a patient's individual medical history and condition. In clinical trials, LY2109761 was given once daily at doses ranging from 50 mg to 300 mg, usually in combination with another medication, such as gemcitabine. Patients should always follow their healthcare provider's dosing instructions carefully and never exceed the recommended dose.
Conclusion:
LY2109761 is a promising new treatment option for patients with various types of cancer, particularly those with tumors that are resistant to chemotherapy or other standard treatments. By inhibiting the TGF-β signaling pathway, it can help slow or stop the growth of cancer cells, potentially leading to improved outcomes for patients. However, like all medications, LY2109761 can have side effects, and it should only be taken under the supervision of a healthcare professional. Patients with cancer should discuss all available treatment options with their healthcare provider to determine the best course of action for their individual case.
